Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer.

ABSTRACT:

SUBMITTER: Zhou T

PROVIDER: S-EPMC11978331 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer.

Zhou Tianyi T Yu Chengtai C Han Yali Y He Bin B Feng Qin Q

Genes & diseases 20241228 4

PMID: 40201140

Similar Datasets

GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer

Project description:Darolutamide is an anti-androgen drug clinically used for prostate cancer therapy. Despite its efficacy, potential drug resistance poses significant challenges in the clinical setting. To better understand the molecular changes resulting from prolonged exposure to darolutamide, we developed a darolutamide-resistant model using LNCaP prostate cancer cells. Through ChIP-seq analysis, we found that a temporary treatment of cells with darolutamide effectively disrupts AR binding to chromatin. However, in darolutamide-resistant cells, the chromatin binding of AR is largely restored. By an integrative analysis of ChIP-seq and RNA-seq, we further identified GATA2, a pioneer factor for AR, substantially upregulated in darolutamide-resistant cells. GATA2 plays an essential role in promoting the proliferation of darolutamide-resistant cells and directly contributes to drug resistance. The ablation of GATA2 by siRNA abolished AR's recruitment to chromatin, leading to a significant reduction in gene expression regulated by AR in these resistant cells. Conversely, the overexpression of GATA2 in prostate cancer cells promoted cell proliferation and resistance to darolutamide. This study demonstrates the significance of GATA2 in the development of darolutamide resistance and suggests GATA2 as a promising therapeutic target to overcome this resistance.

2024-12-31 | GSE249437 | GEO

GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (RNA-Seq)

Project description:Darolutamide is the latest FDA-approved antiandrogen for the treatment of metastatic prostate cancer. Despite its efficacy in prolonging disease-free survival, drug resistance invariably develops. This study aims to understand the molecular mechanisms underlying darolutamide resistance and identify potential therapeutic targets for overcoming the resistance.

2024-12-31 | GSE249436 | GEO

GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (ChIP-Seq)

2024-12-31 | GSE249435 | GEO

GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer

Project description:GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer

| PRJNA1049031 | ENA

GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (ChIP-Seq)

Project description:GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (ChIP-Seq)

| PRJNA1049035 | ENA

GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (RNA-Seq)

Project description:GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (RNA-Seq)

| PRJNA1049034 | ENA

Proteasome-Mediated Regulation of GATA2 Expression and Androgen Receptor Transcription in Benign Prostate Epithelial Cells.

Project description: Not available

| S-EPMC8962351 | biostudies-literature

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer.

Project description: Not available

| S-EPMC6958984 | biostudies-literature

Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators.

Project description: Not available

| S-EPMC10069695 | biostudies-literature

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.

Project description: Not available